Posts by Luke

A six-month freeze on new hospice and home-health Medicare enrollments shows the uncomfortable tradeoff between fighting fraud and preserving access in a fragile health system.

WHO’s Ebola emergency declaration in Congo and Uganda is a reminder that public-health credibility is built before a crisis, not improvised after one begins.

Conflicting mammogram recommendations are not just a medical-information problem. They expose a public-health system that asks citizens to trust institutions while those institutions struggle to speak clearly.

Reuters reports another leadership change at the FDA drug center. The problem is bigger than one official: medical trust breaks when the referee starts looking unstable.

Reuters reports that Amgen’s rare-disease drug Tavneos has been linked to serious liver injuries and about 20 deaths in Japan while the FDA begins withdrawal proceedings in the United States.

The FDA placed a full clinical hold on Aardvark Therapeutics’ ARD-101 trials, a small but telling example of the tension between biotech speed and public trust.

The Supreme Court let mail delivery of mifepristone continue, keeping the abortion-pill fight focused on FDA authority, state power and institutional trust.

A promising experimental pancreatic cancer drug is exposing the gap between FDA access headlines and the real institutional capacity patients need to use them.

A serious anti-fraud effort should protect Medicaid and Medicare. Threatening whole-state funding turns a compliance problem into a structural trust problem.

The Trump administration is pausing new Medicare enrollments for home health and hospice providers, citing fraud concerns and the need for a full accounting.